Revista nº 811

Merino-Coy G, et al. | Mononucleosis en un hospital de segundo nivel asistencial Actual Med. 2020; 105(811): 174- 181 181 1. Dumiere SK, Hogquist KA, Balfour HH. Infectious mono- nucleosis. Curr Top Microbiol Inmunol 2015; 390:211-240. doi: 10.1038/cti.2015.1. 2. Hurt C, Tammaro D. Diagnostic evaluation of mononu- cleosis-like illnesses. Am J Med 2007;120. 911.e1-e8. doi: 10.1016/j.amjmed.2006.12.011. 3. Evans AS. Infectious mononucleosis and related syn- dromes. Am J Med 1978;276(3): 325-39. doi: https://doi. org/10.1097/00000441-197811000-00010. 4. Medovic R, Lgrutinovic Z, Radjevic-Marjanovic R, Marko- vic S, Raskovic Z, Simovic A, et al. Clinical and laboratory differences between Epstein- Barr and cytomegalovirus infectious mononucleosis in children. Serbian Arch Med 2016;144:56e62. doi: 10.2298/sarh1602056m. 5. Luzuriaga K, Sullivan JL. Infectious mononucleosis. N Engl J Med. 2010; 362:1993–2000. doi: 10.1056/NEJM- cp1001116. 6. Cohen JI. Epstein-Barr Virus Infections, Including Infec- tious Mononucleosis. En: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J, editors. Harrison’s principles of internal medicine. 19th ed. New York: Mc- Graw Hill; 2015. 7. Da Paor M, O’Brien K, Fahey T, Smith SM. Antiviral agents for infectious mononucleosis (glandular fever). Cochrane Databse of Systematic Reviews 2016, Issue 12. Art. No.: CD011487. doi: 10.1002/14651858.CD011487.pub2. 8. De Paschale M, Clerici P. Serological diagnosis of Eps- tein-Barr virus infection: Problems and solutions. World J Virol. 2012;1(1):31-43. doi: 10.5501/wjv.v1.i1.31 9. Odumade OA, Hogquist KA, Balfour HH Jr. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev 2011; 24:193–209. doi: 10.1128/CMR.00044-10. 10. Liu H, Gemmell L, Lin R, et al. Development of an Impro- ved Epstein-Barr Virus (EBV) Neutralizing Antibody Assay to Facilitate Development of a Prophylactic gp350-Su- bunit EBV Vaccine. Mediterr J Hematol Infect Dis. 2020;12(1):e2020016. doi: 10.4084/MJHID.2020.016 11. INE: Instituto Nacional de Estadística [Internet]. Madrid: INE; c2020. Cifras oficiales de población resultantes de la revisión del Padrón municipal a 1 de enero 2020. Disponible en: https://www.ine.es/jaxiT3/Tabla.htm?- t=2883&L=0. 12. Topp SK, Rosenfeldt V, Vestergaard H, Christiansen CB, Von Linstow ML. Clinical characteristics and laboratory findings in Danish children hospitalized with primary Eps- tein-Barr virus infection. Infect Dis (Lond) 2015; 47: 908- 914. doi: 10.3109/23744235.2015.1082036 13. Nagpal B, Sreeshyla H, Kishore A, Hegde U, Archana S, Su- mana M. Evaluation of infectious mononucleosis status among a cohort of dental students. Int. J. Adv. Med. 2016, 3, 116. doi: 10.18203/2349-3933.ijam20160201. 14. Dunmire SK, Verghese PS, Balfour HH Jr. Primary Eps- tein-Barr virus infection. J. Clin. Virol. 2018, 102, 84–92. doi: 10.1016/j.jcv.2018.03.001. 15. Jenson HB: Acute complication of Epstein-Barr virus in- fectious mononucleosis. Curr Opin Pediatr 2000, 12:263- 268. doi: 10.1097/00008480-200006000-00016. 16. Balfour HH Jr, Forte FA, Simpson RB, Zolov DM. Penici- llin-related exanthems in infectious mononucleosis iden- tical to those associated with ampicillin. Clin Pediatr. 1972; 11:417–421. doi: 10.1177/000992287201100711 17. Parkin DM. The global health burden of infection-associa- ted cancers in the year 2002. Int J Cancer. 2006;118:3030- 44. DOI: 10.1002/ijc.21731. Los autores/as de este artículo declaran no tener nin- gún tipo de conflicto de intereses respecto a lo ex- puesto en el presente trabajo. CONFLICTO DE INTERESES Si desea citar nuestro artículo: Merino Coy G, Gómez Hervás J, Merino Gálvez E. Repercusión de la mononucleosis infecciosa en un hospital de segundo nivel asistencial. Actual Med. 2020;811(105):174-181. DOI: 10.15568/ am.2020.811.or04 REFERENCIAS BIBLIOGRÁFICAS